SUNPHARMA's weekly performance was lackluster, with a return of -0.05% and a Sharpe Ratio of -0.01, indicating poor risk-adjusted returns. The stock's volatility was moderate at 18.14%, but its Max Drawdown of -1.15% suggests some downside risk. Compared to peers, SUNPHARMA underperformed DRREDDY but outperformed DIVISLAB and HINDUNILVR. Overall, the stock's risk profile was moderate this week.

[Volatility: 18.14%]